The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...

Evrysdi maintains its strong global position ... channel filling we saw immediately after the launch of pre-filled syringe. So we saw a little bit of a spend down in Q4, but we are seeing a ...

Evrysdi generated sales of CHF 1.6 billion ... payments up to an aggregate of $4.00 per share in cash. The prefilled syringe (PFS) of Vabysmo is now approved in the EU for three retinal conditions ...

Please provide your email address to receive an email when new articles are posted on . Evrysdi is the only FDA-approved, noninvasive, disease-modifying treatment for spinal muscular atrophy.

Evrysdi is the only non-invasive disease-modifying treatment for SMA. The 5 mg Evrysdi tablet can either be swallowed whole or dispersed in water. "Evrysdi has robust potential to modify the SMA ...

Basel, 12 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi® (risdiplam ...

Evrysdi is a non-invasive, disease-modifying option that can be swallowed whole or dispersed in water for patients with spinal muscular atrophy. The FDA has approved Roche’s Evrysdi (risdiplam) tablet ...

Now, an approval for a tablet formulation of Roche's Evrysdi can be added to the list of advances in this field over the span of a decade. The FDA on Wednesday gave the thumbs-up to a 5-mg tablet ...